Biogen Acquires Human Immunology Biosciences

The agreement for an acquisition was first announced in May.

Kristen Kazarian, Managing Editor

July 5, 2024

2 Min Read
The acquisition will bolster Biogen's late-stage pipeline, expands Immunology portfolio.Jacob Wackerhausen/iStock/Getty Images Plus via Getty Images

Biogen, a leading biotechnology company that pioneers innovative science to deliver new medicines to patients, has completed the acquisition of Human Immunology Biosciences (HI-Bio).

Biogen and HI-Bio, a privately held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs), first announced the companies had entered into a definitive agreement in May. The agreement stated Biogen would acquire HI-Bio for $1.15 billion upfront and up to $650 million in potential milestone payments.

“We are very excited about the addition of felzartamab into our pipeline, further strengthening our presence in immunology with a promising late-stage therapeutic candidate being studied in multiple indications,” said Priya Singhal, M.D., M.P.H., head of Development at Biogen. “With the transaction now complete, we will begin working together with our colleagues from HI-Bio on plans to advance felzartamab to phase 3 and ultimately deliver innovative treatments to patients with unmet needs across a range of rare diseases.”

An investigational therapeutic human monoclonal antibody directed against CD38 (a protein expressed on mature plasma cells), felzartamab has demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study and from the completed Phase 2 antibody-mediated rejection (AMR) study. These data were presented at the recent European Renal Association Congress in Stockholm. The AMR study data were also published in the New England Journal of Medicine. Felzartamab has also showed proof-of-concept in a Phase 2 study in primary membranous nephropathy (PMN) and there are plans to advance felzartamab to Phase 3 in AMR, IgAN, and PMN.

“I’m looking forward to the important progress HI-Bio will make as part of Biogen, and the power of combining our talented HI-Bio team with Biogen’s global infrastructure to support the development of felzartamab and accelerate Biogen’s expanding immunology portfolio,” said Travis Murdoch, M.D., CEO of HI-Bio. “It’s clear from our engagement over many months —

as we considered how HI-Bio programs could progress in the best possible way — that our teams share many of the same values, including being science-led and execution-focused, and a core mission to positively impact patients with severe diseases.”

About the Author(s)

Kristen Kazarian

Managing Editor

Kristen Kazarian has been a writer and editor for more than three decades. She has worked at several consumer magazines and B2B publications in the fields of food and beverage, packaging, processing, women's interest, local news, health and nutrition, fashion and beauty, automotive, and computers.

Sign up for the Powder & Bulk Solids Weekly newsletter.

You May Also Like